FindTrial
Sign In

To evaluate the prognostic significance of digital PCR monitoring of ctDNA of pediatric acute myeloid leukemia

To evaluate the prognostic significance of digital PCR monitoring of ctDNA of pediatric acute myeloid leukemia

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041879
Enrollment
Unknown
Registered
2021-01-09
Start date
2021-01-04
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric acute myeloid leukemia

Interventions

Gold Standard:Bone marrow morphology
Index test:The&#32
quantitative&#32
changes&#32
of&#32
ctDNA&#32
gene&#32
mutation&#32
frequency/fusion&#32

Sponsors

Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.AML patient, age from 1 to 18 years; 2.Receive standardized treatment.

Exclusion criteria

Exclusion criteria: 1.Acute promyelocytic leukemia; 2.Non-CBF-AML patients without any AML-related gene mutation.

Design outcomes

Primary

MeasureTime frame
Gene mutation frequency;Fusion gene quantification;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactZhu Xiaofan

Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences

xfzhu@ihcams.ac.cn+86 13752090418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026